The Ratings Game: ChemoCentryx shares soar on potential to upend standard of care in vasculitis

This post was originally published on this site

A set of conclusive findings from a late-stage clinical trial testing ChemoCentryx Inc.’s experimental vasculitis treatment surprised company executives and investors, who now say they are bullish on the sales and pipeline potential of avacopan.

Add Comment